Nature of Disclosure: Transcript of the Q1 FY27 Earnings Conference Call, submitted pursuant to Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance for Q1 FY27:

  • Revenue stood at ₹1,476.8 crore (INR 14,768 million), up 22% year-on-year (YoY) and broadly stable sequentially.
  • Gross Margin was healthy at 65.6%, an expansion of 74 basis points YoY.
  • EBITDA was ₹338.9 crore (INR 3,389 million), up 37% YoY, with a margin of 22.9% (expansion of 256 basis points YoY). Sequentially, EBITDA margin declined by 99 basis points.
  • Profit Before Tax (PBT) before exceptional items grew 41% YoY to ₹240.4 crore (INR 2,404 million).
  • Profit After Tax (PAT) grew 60% YoY to ₹180 crore.
  • Return on Capital Improved to 18%.

Balance Sheet & Cash Flow:

  • Net Debt reduced significantly to ₹101.2 crore (INR 1,012 million) in Q1 FY27 from ₹402.1 crore (INR 4,021 million) at FY26 close. Net Debt to EBITDA ratio is 0.07x, making the company nearly debt-free.
  • Net Working Capital to Sales improved to 29% in Q1 FY27 from 30% in Q1 FY26 and Q4 FY26.
  • Operating Cash Flow generation was robust at ₹387.4 crore (INR 3,874 million) in Q1 FY27, compared to ₹100.3 crore (INR 1,003 million) in Q4 FY26.
  • Capital Expenditure (Capex) for the quarter was ₹89 crore (INR 890 million), moderating from ₹100 crore (INR 1,000 million) in Q4 FY26. The full-year capex guidance remains at ₹600 crore, of which ₹89 crore is already spent.

Operational and Strategic Highlights:

  • Business Mix: Growth was led by Finished Dosages, largely contributed by Complex Generics. Complex Generics now constitute 50% of finished dosage sales, up from 39% a year ago.
  • Geographic Performance: Growth was supported by North America and Europe. The Peptide CDMO business (Senn) continued to scale steadily, growing over 100% YoY.
  • R&D Investment: R&D expenses were ₹88 crore (INR 880 million), about 6% of sales, up 30% YoY. Investments are focused on high-barrier areas like CNS, oncology, MUPS, and complex formulations.
  • Gagillapur Facility Update: Remediation work is complete. The company met the FDA in January 2026 and has submitted all responses on time. The agency has not raised concerns on the adequacy or pace of corrective actions. 7 out of 8 facilities have a clean EIR. Awaiting FDA clearance to unlock 9 applications ready to launch from this facility.
  • New Capacity – Genome Valley: The new facility adds about 40% to formulation capacity. It is currently at low utilization, expected to cross 50% by the end of the year. Product transfers and new filings are being made to this site for risk mitigation.
  • U.S. Facility (GPI): The Virginia-based facility received FDA clearance in June 2026. It is currently at ~70% capacity utilization, manufacturing low-volume, high-value products.
  • Peptide CDMO Business (Senn): Q1 revenue was CHF 5 million. The business is project-driven and expects H2 to be stronger than H1. The target is to turn PAT-positive for FY27. The medium-term goal is to achieve USD 50 million in revenue with 30%+ EBITDA margins. Infrastructure upgrades are underway in Zurich. A new peptide intermediate manufacturing facility is planned in Vizag, India, with an estimated capex of ~INR 100 crore for intermediates and ~INR 200 crore for API.
  • Oncology Business: The Vizag plant is focused on oral solid dosage oncology products. The company has 9-13 products in various stages of development, with 2 ANDAs filed in the U.S. and 2 dossiers in Europe. Launches are expected to ramp up from FY28.
  • Controlled Substances: The company is the 4th largest player in the U.S. controlled substance space. It has 4-5 products in the pipeline with IP-based launches expected over the next 1.5-2 years. Growth will also come from increasing market share in existing molecules.
  • Product Pipeline: The company has 18 ANDA approvals pending in the U.S.—9 awaiting facility clearance for Gagillapur and 9 others pending due to IP-related issues (total market size ~$11 billion). It expects ~9 launches in FY27 post-FDA clearance.

Outlook and Guidance:

  • Management expressed confidence in continuing the growth trajectory seen in recent quarters.
  • Gross Margins are expected to remain in the similar range (22-23%), with mix benefits from complex generics offsetting raw material cost inflation.
  • R&D spend is expected to be in the range of 5.5% to 6% of sales going forward.
  • The company will relook at its dividend payout policy, having been conservative historically.

Q&A Key Points:

  • The sequential softness in Europe was attributed to a mix of intentional supply hold due to cost pressures and the paced growth of new approvals.
  • Working capital is expected to be managed efficiently, though receivable days may see a slight increase with growth in non-U.S. markets.
  • Remediation expenses in Q1 were not significant and were in line with recent quarters (less than $1 million per quarter).